Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Heart Disease and Chronic Inflammatory Conditions: New Insights
share announcement

Heart Disease and Chronic Inflammatory Conditions: New Insights

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 10 July 2025 | Viewed by 3034

Special Issue Editors

Dr. Ofer Kobo

E-Mail Website
Guest Editor
Department of Cardiology, Hillel Yaffe Medical Center, Israel
Interests: heart diseases; internal medicine; cardiology; chronic inflammatory
Dr. Gilad Margolis

E-Mail Website
Guest Editor
Division of Cardiovascular Medicine, Hillel Yaffe Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa 38100, Israel
Interests: heart diseases; internal medicine; cardiology

Special Issue Information

Dear Colleagues,

We are delighted to invite scholars and researchers to contribute to a Special Issue of the Journal of Clinical Medicine (JCM) titled “Heart Disease and Chronic Inflammatory Conditions: New Insights”. This issue seeks to explore the multifaceted relationship between cardiovascular diseases and chronic inflammatory states, a topic of increasing importance in clinical and translational research.

Chronic inflammatory conditions, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, are recognized as significant risk factors for the development and progression of heart diseases. Among other mechanisms, the underlying inflammatory processes contribute to endothelial dysfunction, atherosclerosis, and other cardiovascular pathologies. Understanding these connections not only enhances our knowledge of disease mechanisms but also opens the venue for innovative therapeutic strategies and preventative measures.

We encourage submissions of original research articles and reviews that provide new insights into the pathophysiological links, diagnostic advancements, and novel treatments at the intersection of heart disease and chronic inflammation. By fostering a multidisciplinary dialogue, this Special Issue aims to highlight the latest advancements and stimulate further research in this critical area of health.

Dr. Ofer Kobo
Dr. Gilad Margolis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart diseases
  • chronic inflammatory
  • rheumatoid arthritis
  • cardiovascular disease
  • inflammatory bowel disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 854 KiB  
Article
High-Sensitivity CRP and Occurrence of Cancer in Cardiovascular Disease Patients with Cardiovascular
by Orianne de la Brassinne Bonardeaux, Manon Deneye, Cecile Oury, Marie Moonen and Patrizio Lancellotti
J. Clin. Med. 2025, 14(4), 1193; https://doi.org/10.3390/jcm14041193 - 12 Feb 2025
Viewed by 726
Abstract
Background: Many studies recognize a close link between inflammation, cardiovascular disease (CVD), and oncological diseases. High-sensitivity C-reactive protein (hs-CRP), a marker of low-grade systemic inflammation, is a shared feature of these conditions. This retrospective study aims to assess the predictive value of hs-CRP [...] Read more.
Background: Many studies recognize a close link between inflammation, cardiovascular disease (CVD), and oncological diseases. High-sensitivity C-reactive protein (hs-CRP), a marker of low-grade systemic inflammation, is a shared feature of these conditions. This retrospective study aims to assess the predictive value of hs-CRP for the development of cancer in patients with CVD. Methods: Analyzing data from 174 patients undergoing coronary angiography, we assessed hs-CRP levels and collected demographic, biological, and therapeutic data that could influence the studied parameters. Results: Only smoking and dyslipidemia correlated significantly with CRP levels (p = 0.018 and 0.049, respectively). However, hs-CRP did not predict cancer development (p = 0.52) but correlated with 1-year and follow-up mortality (p = 0.011 and 0.021, respectively). Antiplatelet and statin use was higher in the cancer-free group and associated with a lower probability of developing cancer (p < 0.001 and p = 0.009, respectively). Conclusions: While hs-CRP did not prove effective as a cancer predictor in our study, it correlated with all-cause mortality. Our findings suggest a potential protective effect of antiplatelet and statin treatments against cancer development, prompting further research to understand underlying processes and identify key factors in the pathophysiology of these diseases. Full article
(This article belongs to the Special Issue Heart Disease and Chronic Inflammatory Conditions: New Insights)
►▼ Show Figures

Figure 1

13 pages, 1274 KiB  
Article
Prognostic Role of Tissue Iron Deficiency Measured by sTfR Levels in Heart Failure Patients without Systemic Iron Deficiency or Anemia
by Raúl Ramos-Polo, Maria del Mar Ras-Jiménez, Josep Francesch Manzano, Silvia Jovells-Vaqué, Herminio Morillas Climent, Alexandra Pons-Riverola, Sergi Yun Viladomat, Pedro Moliner Borja, Carles Diez-Lopez, José González-Costello, Elena Garcia-Romero, Lorena Herrador, Fernando de Frutos Seminario, Cristina Enjuanes Grau, Marta Tajes Orduña and Josep Comin-Colet
J. Clin. Med. 2024, 13(16), 4742; https://doi.org/10.3390/jcm13164742 - 13 Aug 2024
Cited by 1 | Viewed by 1289
Abstract
Background. Iron deficiency (ID) is a significant, high-prevalence comorbidity in chronic heart failure (HF) that represents an independent predictor of a worse prognosis. However, a clear-cut diagnosis of ID in HF patients is not assured. The soluble transferrin receptor (sTfR) is a [...] Read more.
Background. Iron deficiency (ID) is a significant, high-prevalence comorbidity in chronic heart failure (HF) that represents an independent predictor of a worse prognosis. However, a clear-cut diagnosis of ID in HF patients is not assured. The soluble transferrin receptor (sTfR) is a marker that reflects tissue-level iron demand and may be an early marker of ID. However, the impact of sTfR levels on clinical outcomes in non-anemic HF patients with a normal systemic iron status has never been evaluated. Methods. This is a post hoc analysis of an observational, prospective cohort study of 1236 patients with chronic HF of which only those with normal hemoglobin levels and a normal systemic iron status were studied. The final cohort consisted of 215 patients. Tissue ID was defined as levels of sTfR > 75th percentile (1.65 mg/L). Our aim was to describe the association between sTfR and clinical outcomes (all-cause death and HF hospitalization) and to explore its association with a wide array of serum biomarkers. Results. The sTfR level (HR 1.48, 95% CI 1.13–1.96, p = 0.005) and tissue ID (HR 2.14, 95% CI 1.22–3.75, p = 0.008) was associated with all-cause death. However, we found no association between sTfR levels and the risk of HF hospitalization. Furthermore, high sTfR levels were associated with a worse biomarker profile indicating myocardial damage (troponin and NT-proBNP), systemic inflammation (CRP and albumin), and impaired erythropoiesis (erythropoietin). Conclusions. In this cohort, the presence of tissue ID defined by sTfR levels is an independent factor for all-cause death in patients with normal systemic iron parameters. Full article
(This article belongs to the Special Issue Heart Disease and Chronic Inflammatory Conditions: New Insights)
►▼ Show Figures

Figure 1

Review

Jump to: Research

28 pages, 619 KiB  
Review
Acute Coronary Syndrome and Rheumatic Disease
by Andrew P. Hill, Shaikh B. Iqbal, Brian C. Case, Ananth A. Shankar and Ilan Merdler
J. Clin. Med. 2025, 14(5), 1490; https://doi.org/10.3390/jcm14051490 - 23 Feb 2025
Viewed by 620
Abstract
Patients with rheumatic disease and immune disorders have been noted to show an earlier development of atherosclerosis and to present with acute coronary syndrome. These diseases disproportionately affect women, and patients frequently have a higher number of comorbidities and other risk factors. Inflammation [...] Read more.
Patients with rheumatic disease and immune disorders have been noted to show an earlier development of atherosclerosis and to present with acute coronary syndrome. These diseases disproportionately affect women, and patients frequently have a higher number of comorbidities and other risk factors. Inflammation has long been known to play a role in the development of coronary artery disease. Early studies have shown some benefit in treatment targeting inflammation. While this has not been realized for all populations, there remains potential in treatment with targeted and individualized therapies. Especially since these diseases are associated with a worse prognosis, management benefits from the multidisciplinary expertise of cardiologists, rheumatologists, and other providers. However, the prevention and treatment of underlying rheumatic disease remains essential. This review will seek to highlight prior studies and future directions in the treatment of acute coronary syndrome in patients with rheumatologic disease. Full article
(This article belongs to the Special Issue Heart Disease and Chronic Inflammatory Conditions: New Insights)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop